Healthcare Policy, 19(4) August 2024: 27-31.doi:10.12927/hcpol.2024.27353
Discussion and Debate
Commentary: Which Principles Should Apply for a National Strategy on Rare Diseases?
Abstract
Lexchin and Sirrs (2024) proposed five relevant principles to guide the use of federal funding for expensive drugs for rare diseases, including funding of outcomes-based risk-sharing agreements (OBRSAs) and proactive commitment and participation in the generation of high-quality evidence in a transparent way. This rejoinder, however, questions whether the federal funding should be used only to buy new drugs or whether it could be used to develop new drugs as well. It also examines what OBRSAs would require in terms of institutional capacities to allow the collection of real-world evidence.
This article is for subscribers only.
To view the entire article, sign in if you are a subscriber. Or select one of the options below.
Personal Subscriber? Sign In
Please note: To register for an event you must sign-in as an individual or create a personal Longwood's account. Thank you.
Comments
Be the first to comment on this!
You must sign in to comment Sign In or Create an Account to add comments
Related Content
Healthcare Quarterly
How to Recruit a High-Performing Hospital Board
Healthcare Quarterly
Nursing Leadership